[go: up one dir, main page]

FI973868A0 - D2-vitamiini- tai D4-vitamiinijohdannaisten käyttö sekundaarisen hyperparatyreoosin hoitoon tarkoitettu lääkkeen valmistuksessa - Google Patents

D2-vitamiini- tai D4-vitamiinijohdannaisten käyttö sekundaarisen hyperparatyreoosin hoitoon tarkoitettu lääkkeen valmistuksessa

Info

Publication number
FI973868A0
FI973868A0 FI973868A FI973868A FI973868A0 FI 973868 A0 FI973868 A0 FI 973868A0 FI 973868 A FI973868 A FI 973868A FI 973868 A FI973868 A FI 973868A FI 973868 A0 FI973868 A0 FI 973868A0
Authority
FI
Finland
Prior art keywords
vitamin
medicament
derivatives
manufacture
treatment
Prior art date
Application number
FI973868A
Other languages
English (en)
Swedish (sv)
Other versions
FI973868L (fi
FI973868A7 (fi
Inventor
Joyce C Knutson
Richard B Mazess
Charles W Bishop
Original Assignee
Bone Care Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23645881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI973868(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bone Care Int Inc filed Critical Bone Care Int Inc
Publication of FI973868L publication Critical patent/FI973868L/fi
Publication of FI973868A0 publication Critical patent/FI973868A0/fi
Publication of FI973868A7 publication Critical patent/FI973868A7/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FI973868A 1995-04-03 1996-04-03 D2-vitamiini- tai D4-vitamiinijohdannaisten käyttö sekundaarisen hyper paratyreoosin hoitoon tarkoitettu lääkkeen valmistuksessa FI973868A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/415,488 US5602116A (en) 1988-08-02 1995-04-03 Method for treating and preventing secondary hyperparathyroidism
PCT/US1996/004553 WO1996031215A1 (en) 1995-04-03 1996-04-03 Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism

Publications (3)

Publication Number Publication Date
FI973868L FI973868L (fi) 1997-10-02
FI973868A0 true FI973868A0 (fi) 1997-10-02
FI973868A7 FI973868A7 (fi) 1997-10-02

Family

ID=23645881

Family Applications (1)

Application Number Title Priority Date Filing Date
FI973868A FI973868A7 (fi) 1995-04-03 1996-04-03 D2-vitamiini- tai D4-vitamiinijohdannaisten käyttö sekundaarisen hyper paratyreoosin hoitoon tarkoitettu lääkkeen valmistuksessa

Country Status (17)

Country Link
US (3) US5602116A (fi)
EP (1) EP0820290B1 (fi)
JP (1) JP3529790B2 (fi)
KR (1) KR100432265B1 (fi)
CN (1) CN1214795C (fi)
AU (1) AU719773B2 (fi)
BR (1) BR9604940A (fi)
CA (1) CA2217260C (fi)
DE (1) DE69629184T2 (fi)
ES (1) ES2206570T3 (fi)
FI (1) FI973868A7 (fi)
HU (1) HUP9801777A3 (fi)
MX (1) MX9707535A (fi)
NO (1) NO974480L (fi)
NZ (1) NZ316662A (fi)
PL (1) PL322613A1 (fi)
WO (1) WO1996031215A1 (fi)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US6242434B1 (en) * 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US6566353B2 (en) 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
PL336231A1 (en) * 1997-02-13 2000-06-19 Bone Care International System for aimed therapeutic delivery of vitamin d compounds
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
US5962030A (en) 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
EP2340840B1 (en) * 1998-03-27 2012-08-29 Oregon Health Sciences University Pulse dose Vitamin D drug for the treatment of hyperproliferative skin diseases
US6852760B1 (en) 1998-09-17 2005-02-08 Akesis Pharmaceuticals, Inc. Compositions and methods for treatment for glucose metabolism disorders
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
DK1276482T3 (da) * 2000-03-02 2008-05-26 Univ Pittsburgh Kombinationskemoterapi
IL153378A0 (en) * 2000-07-18 2003-07-06 Bone Care Internat Inc STABILIZED 1alpha-HYDROXY VITAMIN D
WO2002031514A2 (en) * 2000-10-13 2002-04-18 Abbott Laboratories A method of determining the initial dose of vitamin d compounds
US7129230B2 (en) 2001-03-12 2006-10-31 Nestec S.A. Method and product for treating cancer in pets
KR100438254B1 (ko) * 2001-03-29 2004-07-02 아이큐어 주식회사 비타민 ｄ 유사체를 포함하는 매트릭스형 경피흡수제제
ES2192136B1 (es) * 2002-01-04 2005-03-16 Italfarmaco, S.A. Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.
US7566696B2 (en) 2002-09-05 2009-07-28 Wisconsin Alumni Research Foundation Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
WO2004028515A1 (en) * 2002-09-26 2004-04-08 Young-Kweon Choi Matrix type patch for transdermal administration of vitamin d analog and the use thereof
US8093423B2 (en) 2003-02-19 2012-01-10 Globoasia, Llc Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
TWI335218B (en) 2003-02-19 2011-01-01 Panion & Bf Biotech Inc Ferric organic compounds, uses thereof and methods of making same
DE602004002832T2 (de) * 2003-05-07 2007-06-06 Osteologix A/S Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
PT1745791E (pt) * 2003-05-07 2013-07-23 Osteologix As Tratamento de afeções cartilagíneas/ósseas com sais de estrôncio hidrossolúveis
US20060216358A1 (en) * 2003-05-07 2006-09-28 Christian Hansen Controlled release composition containing a strontium salt
WO2005102355A1 (en) * 2004-04-23 2005-11-03 Genzyme Corporation METHODS OF TREATING VARIOUS VITAMIN D METABOLISM CONDITIONS WITH 1α-HYDROXYVITAMIN D2
US20060003950A1 (en) * 2004-06-30 2006-01-05 Bone Care International, Inc. Method of treating prostatic diseases using a combination of vitamin D analogues and other agents
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
EP1848455A1 (en) * 2005-02-14 2007-10-31 Wisconsin Alumni Research Foundation Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
CA2624897C (en) * 2005-10-12 2017-02-14 Proventiv Therapeutics, Llc Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
HUE028029T2 (en) * 2006-01-30 2016-11-28 Panion & Bf Biotech Inc Method of treating chronic kidney disease
EP1993559B1 (en) 2006-02-03 2016-06-22 OPKO Renal, LLC Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
CN103961686A (zh) * 2006-11-16 2014-08-06 凯制药公司 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
CA2684778C (en) * 2007-04-25 2017-09-05 Cytochroma Inc. Methods and compounds for vitamin d therapy
HRP20231142T3 (hr) 2007-04-25 2024-01-05 Eirgen Pharma Ltd. Kontrolirano oslobađanje 25-hidroksivitamina d
JP2010525080A (ja) 2007-04-25 2010-07-22 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー 慢性腎臓病における続発性副甲状腺機能亢進症の安全かつ効果的な治療および予防方法
CA2683628C (en) * 2007-04-25 2018-03-06 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
ES2954932T3 (es) 2008-04-02 2023-11-27 Eirgen Pharma Ltd Métodos, composiciones, usos y kits útiles para la deficiencia de vitamina D y trastornos relacionados
RU2563819C2 (ru) 2009-07-21 2015-09-20 Керикс Байофармасьютикалз, Инк. Лекарственные формы цитрата железа (iii)
SG10201406921SA (en) 2009-07-29 2014-11-27 Kai Pharmaceuticals Inc Therapeutic agents for reducing parathyroid hormone levels
US7886904B1 (en) * 2009-07-30 2011-02-15 Owens Corning Intellectual Capital, Llc Loosefill package for blowing wool machine
WO2011123476A1 (en) 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
CA2698160C (en) * 2010-03-30 2017-07-25 Alphora Research Inc. Stabilized doxercalciferol and process for manufacturing the same
WO2011130668A1 (en) * 2010-04-16 2011-10-20 Baxter International Inc. Therapy prediction and optimization for renal failure blood therapy, especially home hemodialysis
WO2012170955A1 (en) 2011-06-08 2012-12-13 Kai Pharmaceuticals, Inc. Therapeutic agents for regulating serum phosphorus
HK1202086A1 (en) 2011-11-10 2015-09-18 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US9801858B2 (en) * 2014-02-26 2017-10-31 Nippon Zoki Pharmaceutical Co., Ltd. Progress-supressing or improving agent for chronic kidney disease
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP6520510B2 (ja) * 2015-07-15 2019-05-29 富士ゼロックス株式会社 情報処理装置及び情報処理プログラム
CN108883120A (zh) 2016-03-28 2018-11-23 欧普科爱尔兰环球控股有限公司 维生素d治疗方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907843A (en) * 1974-06-14 1975-09-23 Wisconsin Alumni Res Found 1{60 -Hydroxyergocalciferol and processes for preparing same
US4202829A (en) * 1978-01-05 1980-05-13 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4260549A (en) * 1979-05-21 1981-04-07 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4195027A (en) * 1978-01-16 1980-03-25 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxylated compounds
US4225596A (en) * 1978-10-13 1980-09-30 Wisconsin Alumni Research Foundation Method for treating calcium imbalance and improving calcium absorption in mammals
US4234495A (en) * 1979-09-10 1980-11-18 Wisconsin Alumni Research Foundation Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds
US4554106A (en) * 1984-11-01 1985-11-19 Wisconsin Alumni Research Foundation Method for preparing 1α-hydroxyvitamin D compounds
US4555364A (en) * 1984-11-01 1985-11-26 Wisconsin Alumni Research Foundation Method for preparing 1-hydroxyvitamin D compounds
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
GB2229921B (en) * 1989-04-05 1992-12-16 Chugai Pharmaceutical Co Ltd Treatment for hyperparathyroidism with use of vitamin d derivatives
ES2169023T3 (es) * 1990-09-21 2002-07-01 Bone Care Int Inc Nueva 1alfa-hidroxi vitaminada d4 y nuevos intermedios y analogos.
DK0550702T3 (da) * 1991-01-08 1999-11-01 Bone Care Int Inc Fremgangsmåde til fremstilling og anvendelse af 1alfa,24-dihydroxy-vitamin D2
JP3030157B2 (ja) * 1991-03-13 2000-04-10 株式会社クラレ シクロヘキサントリオール誘導体
AU682817B2 (en) * 1992-01-29 1997-10-23 Bone Care International, Inc. 1alpha-hydroxy-24-(epi)-vitamin D4
EP0562497A1 (en) * 1992-03-27 1993-09-29 Nisshin Flour Milling Co., Ltd. 1 alpha-hydroxy vitamins D7 and D4' processes for the preparation thereof and pharmaceutical compositions
AU4841193A (en) * 1992-08-28 1994-03-29 Lunar Corporation 1alpha,24(S)-dihydroxy vitamin D2, its formation and use
US5350745A (en) * 1993-01-29 1994-09-27 Lunar Corporation Treatment of myocardial failure

Also Published As

Publication number Publication date
EP0820290A1 (en) 1998-01-28
WO1996031215A1 (en) 1996-10-10
DE69629184T2 (de) 2004-05-06
US5861386A (en) 1999-01-19
CN1185109A (zh) 1998-06-17
NO974480L (no) 1997-11-14
CN1214795C (zh) 2005-08-17
US5602116A (en) 1997-02-11
MX9707535A (es) 1998-07-31
NO974480D0 (no) 1997-09-29
ES2206570T3 (es) 2004-05-16
HUP9801777A2 (hu) 1998-11-30
DE69629184D1 (de) 2003-08-28
EP0820290B1 (en) 2003-07-23
JPH11503164A (ja) 1999-03-23
HUP9801777A3 (en) 1999-05-28
FI973868L (fi) 1997-10-02
AU5384096A (en) 1996-10-23
CA2217260C (en) 2000-08-01
AU719773B2 (en) 2000-05-18
KR19980703537A (ko) 1998-11-05
BR9604940A (pt) 1998-06-09
NZ316662A (en) 2001-04-27
JP3529790B2 (ja) 2004-05-24
CA2217260A1 (en) 1996-10-10
US5707980A (en) 1998-01-13
FI973868A7 (fi) 1997-10-02
PL322613A1 (en) 1998-02-02
KR100432265B1 (ko) 2004-09-10
HK1008180A1 (en) 1999-05-07

Similar Documents

Publication Publication Date Title
FI973868L (fi) D2-vitamiini- tai D4-vitamiinijohdannaisten käyttö sekundaarisen hyperparatyreoosin hoitoon tarkoitettu lääkkeen valmistuksessa
FI956227L (fi) Sisäänhengitykseen tarkoitettu terapeuttinen valmiste
AU7578696A (en) Morpholine derivatives and their use as therapeutic agents
DE69624072D1 (de) Wegwerfschutzmaske
FI955942A7 (fi) Kertakäyttöinen absorboiva tuote, joka on tarkoitettu matalaviskositee ttisia eritteitä varten
AU4050195A (en) Soft gelatin pharmaceutical dosage form
CY2007001I1 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
AU3541095A (en) Surgical face mask
FI952721L (fi) Aine maksa-sappi-sairauksien hoitamiseksi
NO308854B1 (no) Terapeutiske forbindelser, farmasøytisk akseptable salter og formuleringer inneholdende forbindelsene, samt anvendelser derav
FI956014L (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
EE03878B1 (et) 5-O-desosaminüül-6-O-metüülerütronoliid A derivaadid, nende valmistamismeetod ja kasutamine bioaktiivsete ühendite valmistamiseks
EE9700168A (et) Teraapias kasutatavad bitsüklilised isotiokarbamiidi derivaadid
GB2319729B (en) A film for topical use in the treatment of wounds
EP0765661A3 (en) Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of glumerulonephritis
EE03384B1 (et) Melatoniini kasutamine ravimi tootmiseks
PT866699E (pt) Utilizacao de inibidores de colinesterase para o fabrico de um medicamento para o tratamento de xerostomia
AU7726796A (en) Use of 3-oxa-d-prostaglandins for the manufacture of a medicament for the treatment of glaucoma
LV11966A (lv) Pretiekaisumu lidzeklis arigai lietosanai
FI942803L (fi) Ipsapironi-lääkevalmiste
IL117465A (en) Use of certain cystine derivatives for the preparation of a medicament for the treatment of restenosis
AU4297696A (en) Use of a vitamin of the k group for treating hyperparathyroidism
KR970003938U (ko) 환자 보조용 헬멧
KR950029532U (ko) 환자용 기저귀
FI951041A7 (fi) (S)-(-)-alfa-etyyli-2-okso-1-pyrrolidiiniasetamidin käyttö valmistettaessa farmaseuttinen valmiste ahdistuksen hoitoon